Gastric cancer, characterized by its high incidence and lethality, is a major malignancy affecting life expectancy worldwide, especially in East Asia, and has seen little clinical progress in recent years, with most studies ending in negative results. Immunotherapy has emerged in the field of oncology treatment, and this article will review the field of immunotherapy in gastric cancer. Relay immune cell therapy, it has been documented that the number of immune cells infiltrating in the tumor has a strong relationship with better prognosis of the patient. Patients receiving organ transplants, who are taking immunosuppressive drugs, are unable to activate T cells effectively in the body, which greatly increases the chance of tumor development, proving the centrality of cellular immunity in tumor immunity. Although up to now, the FDA has not approved any of the pericyte therapies for gastric cancer, with the advancement of tumor-related research and immune cell technology, pericyte therapy is expected to become one of the clinical treatment options for gastric cancer. Cytotoxic T lymphocyte (CTL) culture techniques are well established and have been well reported in many types of tumors. Some investigators have used Survivin peptide-activated CTL to kill cell lines and primary cells from gastric cancer patients, showing some promise for application. Other researchers have used mitotic kinesin (MCAK) peptide to stimulate CTL via antigen-presenting cells, and the resulting CTL was effectively killed in an HLA-I-restricted manner in MCAK-expressing gastric and intestinal cancer cells. Some investigators have also isolated peripheral blood single nucleated cells from patients for CIK cell culture and achieved definite tumor suppression in both in vitro studies and in nude mouse tumor models. Several clinical studies have confirmed that CIK cell infusion in combination with chemotherapy can effectively reduce the serum tumor marker levels of patients and improve their quality of survival and overall survival, showing excellent clinical application. Dendritic cells, the initial stage of the body’s fight against tumors is the recognition, endocytosis, processing and delivery of tumor antigens to effector T cells by antigen-presenting cells, mainly dendritic cells, which have a very important role in tumor immunity. Several studies have demonstrated that infiltrating dendritic cells in tumors correlate significantly with five-year survival of patients. In a phase I clinical report, investigators treated patients with gastric cancer with Her-2 peptide-loaded dendritic cells. In one of nine patients, serum CEA and CA199 levels decreased, and in two other patients, tumors shrank by more than 50%, and no significant adverse effects were reported. In another phase I clinical report, investigators applied MAGE-3 peptide-loaded dendritic cells to treat 12 patients with progressive gastrointestinal tumors, among which three patients showed tumor shrinkage and seven patients showed a decrease in serologic tumor marker levels, which generally showed good clinical application. Immune node monoclonal antibody therapy, CTLA4 and PD1 are immune node molecules that effector T cells are unable to play a role in killing. monoclonal antibody. In a phase II study, 18 patients were enrolled, and the median survival of patients for whom an immune response could be observed in vivo was 17.1 months, while the survival of non-responders was only 4.7 months, and one patient was still alive after 32.7 months of treatment, initially demonstrating the potential of CTLA4 monoclonal antibody in gastric cancer. The KEYNOTE-012 study looked at the initial effect of Pembrolizumab, a PD1 monoclonal antibody, in treating gastric cancer, with an overall efficacy rate of 30.8%, 41% of patients having tumor shrinkage, and a six-month survival rate of 69%, further increasing the proportion of people who benefited. Gastric cancer is a large group of very heterogeneous tumors, and the progress of traditional chemotherapy and targeted drugs is very limited, while the recent progress related to immunotherapy has shown the first signs, and we can expect more therapeutic effect of immunotherapy in gastric cancer.